Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS

• Status: Unknown status
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Rosuvastatin reload may prevent myocardial damage in ACS patients undergoing PCI

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beijing Anzhen Hospital
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• 18-75 year old

• diagnosed as acute coronary syndrome

• Plan to PCI

Exclusion Criteria:

• STEMI patient

• emergency PCI(<2h) for NSTE-ACS

• History of liver disease and myopathy (ALT/AST>3 x upper limit of normal,CK>5 x upper limit of normal)

• TG>500mg/dl,CCr<30ml/min

• inflammatory disease

• allergic to rosuvastatin

• nephrotic syndrome,hypothyroidism,systemic lupus erythematosus,myeloma,et.al.